Wellness
Incannex Seeks FDA Approval for Psilocybin-Assisted Psychotherapy Program
An independent review supported earlier positive findings.
The post Incannex Seeks FDA Approval for Psilocybin-Assisted Psychotherapy Program appeared…
Clinical-stage pharmaceutical Incannex Healthcare Ltd. (Nasdaq: IXHL) is moving forward with a new psychotherapy treatment program using psilocybin, the company announced Thursday.
The Melbourne, Australia-based firm will ask the U.S. Food and Drug Administration for the green light to begin clinical trials in the U.S. for its Psi-GAD therapy. Its subsidiary, Psychennex Pty Ltd, started preparing an investigational new drug application to submit to the FDA.
The company expects the final results from their current trial by early 2024 at the latest. The application to the FDA will detail the safety, effectiveness, quality, and other data about the firm’s psilocybin treatment.
Earlier this year, preliminary results from a Phase 2 trial at Monash University indicated that the psilocybin treatment likely had a noticeable benefit over a placebo.
“Interim statistical analysis predicted that there was a greater than 85% chance of the trial showing statically significant benefit for the psilocybin treatment arm versus the placebo arm at the conclusion of the trial period,” the company wrote.
An independent review supported these findings and saw no safety concerns, it said.
“The interim analysis and the progress made by Dr. Liknaitsky and his team at Monash University has empowered us to fast-track various strategic business decisions to hasten the development of the therapy,” CEO Joel Latham said in a statement.
“Our organization is consistently fortifying its position as a frontrunner within the psychedelic research sector, and we eagerly anticipate the results from our Phase 2 trial upon its completion.”
The announcement received approval from Incannex’s board.
The post Incannex Seeks FDA Approval for Psilocybin-Assisted Psychotherapy Program appeared first on Green Market Report.
application
therapy
psilocybin
psychedelic
psychotherapy
fda
research
clinical trials
nasdaq
healthcare
Lion’s Mane Mushroom: History, Benefits, and Adaptogen Properties
Explore the intriguing world of Lion’s Mane Mushroom in our comprehensive guide. Dive into its unique properties, historical significance, and myriad health…
AI can already diagnose depression better than a doctor and tell you which treatment is best
Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…
Reasons You should Get this: Neptune Wellness Solutions Inc (NASDAQ:NEPT), WeTrade Group Inc. (NASDAQ:WETG)
NEPT has seen its SMA50 which is now -9.28%. In looking the SMA 200 we see that the stock has seen a -92.25%. WETG has seen its SMA50 which is …
The…